Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12.
Commun Med (Lond)
; 3(1): 40, 2023 Mar 25.
Article
en En
| MEDLINE
| ID: mdl-36966232
Some viruses, including the herpes virus, can be modified so that they can target and kill cancers. These viruses can be loaded with factors that stimulate the immune system, which can help to eradicate cancer cells. Here, we test different methods of loading a cancer-killing version of the herpes virus with interleukin 12, an immune-stimulating factor. We show that one method, which involves loading the virus with the different parts of interleukin 12 fused together, is superior to another, and leads to improved anti-cancer effects in mouse models. These findings have contributed to the creation of a cancer-killing virus that is currently in clinical trials in patients with melanoma.
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Commun Med (Lond)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Japón